The Rogosin Institute Inc is categorized under Medical Research in New York City, NY and active since 1963.
The Rogosin Institute Inc was established in 1963, and today employs 1 to 4, earning $20.000.000 to $49.9999.999 per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Albert L Rubin at the company’s headquarters by writing to 505 East 70th St Floor 2, New York City, New York NY 10021 or by phoning (212) 746-1551. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | The Rogosin Institute Inc |
Contact Person: | Albert L Rubin |
Address: | 505 East 70th St Floor 2, New York City, New York 10021 |
Phone Number: | (212) 746-1551 |
Website Address: | rogosin.org |
Annual Revenue (USD): | $20.000.000 to $49.9999.999 |
Founded: | 1963 |
Location Type: | Headquarters |
Employee Number: | 1 to 4 |
Business Type: | B2B (Business to Business) |
Business Category: | Medical Research |
SIC Code: | 8733 |
NAICS Code: | 541720 |
Share This Business: |
The Rogosin Institute Inc was started in 1963 to provide professional Medical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $20.000.000 to $49.9999.999 per annum.
Feel free to contact Albert L Rubin for inquiries that concern The Rogosin Institute Inc by calling the company number (212) 746-1551, as your correspondence is most welcome. Additionally, the physical location of the headquarters of The Rogosin Institute Inc can be found at the coordinates 40.765509,-73.954236 as well as the street address 505 East 70th St Floor 2 in New York City, New York 10021.
For its online presence, you may visit The Rogosin Institute Inc’s website at rogosin.org and engage with its social media outlets through on Twitter and on Facebook.